Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Prospective Observational Immunogenicity Trial of Gardasil-9 HPV Vaccine in People Living With Adequately Managed HIV
Louisiana State University Health Sciences Center in New Orleans
250 participants
Nov 30, 2022
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, and to determine the protection afforded by Gardasil vaccine over time in previously vaccinated adults living with HIV. The clinical hypothesis is that adults with virologically controlled HIV mount a serum antibody response to the nonavalent HPV vaccine that is comparable to HIV negative counterparts. We also postulate that HPV vaccination will provide short-term clinical benefit against HPV infections and disease associated with vaccine genotypes and continuing protection against vaccine genotypes of HPV over time.
Eligibility
Inclusion Criteria6
- HIV seropositive
- immune intact (CD4+ T cell count in peripheral blood \>200 cells/ml)
- HIV controlled (peripheral blood HIV viral load \<1,000 genome copies/mL)
- Stable on antiretroviral regimen for ≥3 months
- Gardasil-9 naive and age ≤45 OR
- documented receipt of 3 doses of Gardasil-4 or Gardasil-9 HPV vaccine
Exclusion Criteria8
- Medical contraindication for vaccination (vaccine-naive arm only)
- Women who are pregnant
- Acute illness
- Taking chronic steroids, \>0.5mg/kg prednisone or equivalent
- Taking immune modulating medications
- Received blood transfusion/blood products within the past 6 months
- Recipients of other vaccine products within the past month
- Inability to provide informed written consent
Interventions
Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)
Subunit vaccine against four (6, 11, 16, 18) or nine (6, 11, 16, 18, 31, 33, 45, 52, 58) genotypes of human papillomavirus. Administered as part of participant's clinical care prior to study enrollment (intervention not delivered as part of study design).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05266898